Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Clinical characteristics and prognostic factors in myeloid blast-Phase chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

HZHuifang ZhaoYZYingling ZuYZYanli Zhang

Discussion

Loading...

Member takes

Overview

Analysis reveals treatment response and additional chromosomal abnormalities impact prognosis in chronic myeloid leukemia patients.

Key Points

  • Overall survival at 5 years is only 15% for blast-phase chronic myeloid leukemia patients, indicating a poor prognosis.
  • In a cohort of 141 patients, the major hematologic response rate was 53.8%, demonstrating treatment effectiveness.
  • Retrospective review of clinical records highlights the significance of tyrosine kinase inhibitors and their impact on treatment response.
  • Prior third-generation TKI use remains a critical adverse prognostic factor in determining survival outcomes.

Cite This Study

Zhao et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6bchttps://doi.org/10.1182/blood-2025-7287
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase2025
  2. 2Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia2025
  3. 3Clinico-hematological characteristic, lipogram, and some metabolic alteration in chronic phase chronic myeloid leukemia in a patient treated with Tyrosine kinase inhibitor2026
  4. 4Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor2025
  5. 5Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025